Annexon, Inc. ANNX 深 沪
等待开盘 02-10 09:30:00 美东时间
5.63
-0.100
-1.75%
华盛通- 最 高5.71
- 今 开5.71
- 成交量 171.65万股
- 最 低 5.46
- 昨 收 5.73
- 总市值 8.39亿
- 52周最高 7.18
- 市盈率 静 --
- 换手率 1.15%
- 52周最低 1.285
- 委 比 17.99%
- 总股本 1.49亿
- 历史最高 38.01
- 量 比 0.92
- 振 幅 4.36%
- 历史最低 1.285
- 每 手 1
- 风险率 1.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Alpha Buying: Managing Biotech Risk With Insider Clues
Biotech stocks have a way of making smart people do dumb things. It starts inno...
01-16 00:32
Annexon Submits Marketing Authorization Application To EMA For Tanruprubart For Treatment Of Guillain-Barré Syndrome
Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of CareBLA Submission with U.S./European Data from FORWARD Trial Planned in 2026BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) --
01-08 21:15
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
<p>Annexon, Inc. announced that its CEO, Douglas Love, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The presentation will be webcast live and available for replay on Annexon's website for 30 days. Annexon focuses on targeted immunotherapies for neuroinflammatory diseases affecting nearly 10 million people globally.</p>
01-07 21:05
Vizsla, Coty, Kalaris, Annexon, Brown & Brown Trending
Analysts are intrested in these 5 stocks: ( ($VZLA) ), ( ($COTY) ), ( ($KLRS) )...
2025-12-27 17:01
美股大行评级 | 潜在涨幅63.56%！拜玛林制药获Truist Securities升目标价至100美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持拜玛林制药"买入"评级，目标价从80美元升至100美元；HC Wainwright & Co.：维持Savara"买入"评级，目标价从8美元升至10美元
2025-12-24 11:17
Chardan Capital Initiates Coverage On Annexon with Buy Rating, Announces Price Target of $16
Chardan Capital analyst Daniil Gataulin initiates coverage on Annexon (NASDAQ:ANNX) with a Buy rating and announces Price Target of $16.
2025-12-23 21:52
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. granted stock options to a new non-executive employee under its 2022 Employment Inducement Award Plan, approved on December 10, 2025. The employee received an option to purchase 19,000 shares with an exercise price of $4.91, vesting over four years. Annexon develops complement inhibitors targeting neuroinflammation caused by C1q activation, addressing autoimmunity, neurodegeneration, and ophthalmology diseases. Its mission is to del...
2025-12-17 00:31
美股大行评级 | 最高500美元！MongoDB获18家大行紧急上调目标价；巴克莱下调理想汽车目标价至18美元
今日重点评级关注：B. Riley证券：维持Seabridge Gold"买入"评级，目标价从50美元升至65美元；HC Wainwright & Co.：维持TRX Gold"买入"评级，目标价从1.2美元升至1.4美元
2025-12-03 09:58
Clear Street Initiates Coverage On Annexon with Buy Rating, Announces Price Target of $17
Clear Street analyst Bill Maughan initiates coverage on Annexon (NASDAQ:ANNX) with a Buy rating and announces Price Target of $17.
2025-12-02 22:06
Annexon stock rises after director purchases shares
Annexon (ANNX) stock rose after the company's director disclosed a purchase of shares for an approximate value of about $5M. The stock is up about 15% today. Muneer Satter, director at Annexon, bought...
2025-11-21 01:02
